Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status Prescription
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 43598-678; 59572-740; 16729-306; 71288-115; 16714-927; 0781-3253; 43598-305; 71288-153; 63592-1800; 68001-313; 63759-0015; 67457-254; 59572-730; 70121-1237; 68001-527; 72606-558; 69097-805; 69097-368; 0781-9253; 59572-102; 64679-096; 68554-0104; 66529-0013; 63660-0010; 14096-121; 51991-797; 42385-719; 63323-771; 51916-350; 68001-504; 65129-1222; 72485-201; 43598-465; 53183-4011; 0143-9606; 43817-906; 54893-0029
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Procedural pain12.02.05.007; 08.01.08.009--Not Available
Bone marrow failure01.03.03.0050.008259%
Acute promyelocytic leukaemia differentiation syndrome22.02.01.023; 12.03.01.0420.001598%
Iron overload14.13.03.002; 12.02.08.0050.000278%
Acute graft versus host disease12.02.09.002; 10.02.01.0280.000695%Not Available
Chronic graft versus host disease12.02.09.003; 10.02.01.0290.000556%Not Available
Cytopenia01.03.03.0120.003463%Not Available
Haematological malignancy16.21.01.002; 01.13.01.0030.000139%Not Available
Treatment failure08.06.01.0170.002432%Not Available
Oral herpes11.05.02.005; 07.05.07.0020.000799%Not Available
Pharyngeal disorder22.04.05.0070.000533%Not Available
Myelodysplastic syndrome transformation16.01.04.005; 01.10.04.0050.001598%Not Available
Organising pneumonia22.01.02.0080.007193%Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.003--Not Available
Abdominal wall haemorrhage24.07.02.036; 07.16.05.0020.000533%Not Available
Skin mass23.07.04.0140.000533%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
Upper-airway cough syndrome22.02.05.030--
Craniocerebral injury17.11.01.007; 12.01.10.0120.000139%Not Available
Procedural haemorrhage12.02.05.036; 24.07.01.0530.000533%
Functional gastrointestinal disorder07.11.01.0160.000533%Not Available
Neuropsychiatric syndrome19.07.03.009; 17.02.10.0140.000139%Not Available
Central nervous system haemorrhage24.07.04.016; 17.08.01.0350.000139%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
Refractory cytopenia with unilineage dysplasia16.01.04.007; 01.10.04.0070.000139%Not Available
Colonic abscess11.01.07.024; 07.19.01.0130.000208%Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.000278%Not Available
Candida infection11.03.03.0210.001066%
Aspergillus infection11.03.01.0040.000556%Not Available
The 22th Page    First    Pre   22 23 24    Next   Last    Total 24 Pages